Related Experiment Videos
[Therapy of bronchitis in childhood with Eprazinone (author's transl)]
Insights
Eprazinone effectively treats acute and chronic bronchitis in children, demonstrating excellent mucolytic activity for symptom relief. This new bronchosecretolytic substance offers a promising therapeutic option for pediatric respiratory conditions.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchitis is a common respiratory illness in children, often leading to significant morbidity.
- Effective mucolytic agents are crucial for managing airway mucus hypersecretion in pediatric bronchitis.
Purpose of the Study:
- To evaluate the therapeutic efficacy of Eprazinone, a novel bronchosecretolytic agent.
- To assess the mucolytic activity and symptomatic improvement in children with acute and chronic bronchitis treated with Eprazinone.
Main Methods:
- A study involving two groups of pediatric patients: 10 with acute bronchitis (5-14 years) and 12 with chronic bronchitis (7-14 years).
- Daily laboratory and check-up examinations were conducted to objectify treatment effects.
- Treatment involved Eprazinone administered as 3x1 tablets/day for school children and 2x1 suppositories/day for younger children over 5-8 days.
Main Results:
- Eprazinone demonstrated significant symptomatic improvement in both acute and chronic bronchitis groups.
- The substance exhibited excellent mucolytic activity, aiding in mucus clearance.
- Treatment was well-tolerated over the 5-8 day course in both pediatric cohorts.
Conclusions:
- Eprazinone is an efficient and effective remedy for the symptomatic treatment of acute and chronic bronchitis in children.
- The drug's potent mucolytic properties make it a valuable therapeutic option for pediatric airway diseases.
Abstract:
This study should demonstrate the efficiency of a new bronchosecretolytic substance, Eprazinone, in therapy of acute and chronic bronchitis with children. The following groups of children have been treated: 1) 10 children with acute bronchitis (aged 5-14 years); 2) 12 children with chronic bronchitis (aged 7-14 years). To objectivize the effect of the substance, exact laboratory- and check-up examinations have been done daily. The dose was 3 x 1 tablet/day for school children, for younger children 2 x 1 suppository daily. All children have been treated over 5-8 days. The results of the therapy with Eprazinone in both groups show that -Eprazinone is an efficient remedy to cure symptomatically chronic and acute bronchitis in children. It shows an excellent mucolytic activity.